Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
出版年份 2015 全文链接
标题
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
作者
关键词
-
出版物
Scientific Reports
Volume 5, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-07-11
DOI
10.1038/srep12122
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study
- (2014) Maryam Fouladi et al. PEDIATRIC BLOOD & CANCER
- Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
- (2013) Vikram Deshpande et al. BMC CANCER
- Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
- (2012) C. Parikh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Common ABCB1 polymorphisms associated with susceptibility to infantile spasms in the Chinese Han population
- (2011) L. Dong et al. GENETICS AND MOLECULAR RESEARCH
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
- (2010) Jieru Meng et al. CANCER BIOLOGY & THERAPY
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness
- (2010) Sung Yong Oh et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma
- (2010) Jens Kruth et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells
- (2010) Kawin Leelawat et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2010) Jieru Meng et al. PLoS One
- Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
- (2009) Suee Lee et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Akt as a therapeutic target in cancer
- (2008) Linda S Steelman et al. EXPERT OPINION ON THERAPEUTIC TARGETS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now